Thompson Investment Management buys $4,338,832 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Thompson Investment Management scooped up 47,423 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 70,642 shares of AbbVie Inc which is valued at $4,338,832.AbbVie Inc makes up approximately 0.89% of Thompson Investment Management’s portfolio.

AbbVie Inc closed down -0.23 points or -0.38% at $60.7 with 66,79,223 shares getting traded on Wednesday. Post opening the session at $60.93, the shares hit an intraday low of $60.25 and an intraday high of $61.48 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Transamerica Financial Advisors reduced its stake in ABBV by selling 5,579 shares or 86.72% in the most recent quarter. The Hedge Fund company now holds 854 shares of ABBV which is valued at $52,453.Private Bank Trust Co reduced its stake in ABBV by selling 348 shares or 1.68% in the most recent quarter. The Hedge Fund company now holds 20,332 shares of ABBV which is valued at $1,248,791. AbbVie Inc makes up approx 0.21% of Private Bank Trust Co’s portfolio.Oregon Public Employees Retirement Fund boosted its stake in ABBV in the latest quarter, The investment management firm added 4,408 additional shares and now holds a total of 218,556 shares of AbbVie Inc which is valued at $13,006,268. AbbVie Inc makes up approx 0.30% of Oregon Public Employees Retirement Fund’s portfolio. Santa Fe Partners sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 14,877 shares of ABBV which is valued $885,330. Independent Portfolio Consultants added ABBV to its portfolio by purchasing 12,005 company shares during the most recent quarter which is valued at $714,418. AbbVie Inc makes up approx 0.20% of Independent Portfolio Consultants’s portfolio.

On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.